A Study Assessing KB407 for the Treatment of Cystic Fibrosis

Launched by KRYSTAL BIOTECH, INC. · Aug 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called KB407 for adults with cystic fibrosis (CF), a condition that affects the lungs and digestive system. The main goal of this study is to see how safe and tolerable different doses of KB407 are when given through a nebulizer, which is a device that turns liquid medicine into a mist that can be inhaled. The trial is currently recruiting participants aged 18 and older who have been diagnosed with cystic fibrosis and are in stable condition. To be eligible, individuals must also have certain lung function levels and be able to follow study instructions.

If you join this trial, you can expect to receive nebulized doses of KB407 while being closely monitored by healthcare professionals. They will check your health and how well your body responds to the treatment. It's important to know that there are specific criteria that exclude some individuals, such as those who have had recent infections or changes in their CF treatment. Overall, this study aims to help researchers understand if KB407 could be a safe option for treating cystic fibrosis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The subject must have read, understood, and signed an Institutional Review Board/Ethics Committee (IRB/IEC) approved Informed Consent Form and must be able to and willing to follow study procedures and instructions
• • 2. Subjects aged 18 years or older at the time of Informed Consent
• 3. A confirmed diagnosis of CF as defined by clinical signs and symptoms of CF and at least one of the following:
• • A historical sweat chloride value \>60 mmol/L
• • Two copies of a disease causing mutation in the CFTR gene
• • 4. Clinically stable in the opinion of the Investigator
• • 5. Percent predicted FEV1 ≥40% and ≤100% of the predicted normal for age, gender, and height at Screening
• • 6. Resting oxygen saturation ≥92% on room air at Screening
• Exclusion Criteria:
• • 1. Initiation of any new chronic therapy (eg, CFTR modulator, hypertonic saline, inhaled antibiotic) or any change in chronic therapy (excluding pancreatic enzyme replacement therapy) within 28 days prior to the first dose
• • 2. Hospitalization, sinopulmonary infection, CF exacerbation, or other clinically significant infection or illness 14 days prior to the first dose that, in the opinion of the Investigator, may confound study results
• • 3. Treatment for Burkholderia cenocepacia, Burkholderia dolosa, or Nontuberculosis Mycobacteria infection within 3 months prior to the first dose
• • 4. Participation in another clinical study or treatment with an investigational agent 30 days or 5 half-lives, whichever is longer, prior to the first dose
• • 5. History of or listed for solid organ transplantation
• • 6. Any condition (including a history or current evidence of substance abuse or dependence, uncontrolled asthma, or is considered to be immunocompromised) that, in the opinion of the Investigator, would impact a subject's ability to complete all study-related procedures and/or poses an additional risk to the assessment of safety of KB407
• • 7. An active oral herpes infection 30 days prior to the first dose
• • 8. Has received a vaccine within 72 hours prior to the first dose or has a planned vaccination during the treatment period
• • 9. Women who are pregnant or nursing
• • 10. Subject who is unwilling to comply with contraception requirements per protocol
• • 11. Clinically significant abnormalities of hematology or chemistry testing at Screening that the Investigator believes may interfere with the assessment of safety and/or efficacy of the study treatment
• • 12. Subject has a known hypersensitivity to inhaled glycerol
• • 13. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol in the opinion of the Investigator
• • 14. Bronchoscopy participants only: Unable to tolerate bronchoscopy procedure and airway sampling, in the opinion of the Investigator